Navigation Links
BioMS Medical announces second quarter 2009 results
Date:7/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, July 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the three and six months ended June 30, 2009.

"The pivotal phase III MAESTRO-01 trial has completed the last patient last visit, and we are expecting results from this study within the second half of this year. This is the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis and with a positive outcome, our drug could represent a valuable new treatment for MS patients," said Kevin Giese, President and CEO of BioMS Medical.

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

    -   MAESTRO-01: This pivotal phase III trial is being conducted in Canada
        and Western Europe, involving 611 SPMS patients at 47 trial sites in
        ten countries. The primary clinical endpoint for MAESTRO-01 (and
        MAESTRO-03) is defined as a statistically and clinically significant
        increase in the time to progression of the disease as measured by the
        Expanded Disability Status Scale (EDSS), in patients with HLA-DR2
        and/or HLA-DR4 immune response genes.

    -   MAESTRO-02: Eligible patients who have successfully completed
        MAESTRO-01 may choose to receive dirucotide on an un-blinded basis in
        this open-label follow-on study regardless of whether they were
        previously on placebo or drug. To date, approximately 95% of the
        eligible patients who have successfully completed the MAESTRO-01
        trial have enrolled in this follow-on study.

    -   MAESTRO-03: Enrollment was initiated in June 2007 and completed on
        August 1, 2008 for this pivotal U.S. phas
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
2. BioMS Medical to participate in panel session at Bio International Convention 2009
3. BioMS Medical Announces First quarter 2009 results
4. BioMS Medical to present at Alberta Economic Forum in Geneva
5. BioMS Medical to present at BioFinance 2009
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. BioMS Medical Announces 2008 Year End Results
9. BioMS Medical warrant extension
10. BioMS Medical to present at BIO CEO and Investor Conference
11. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... today the establishment of a collaboration with Ono ... and development of small molecule modulators of an ... terms of the agreement, Receptos will use its ... crystal structures of the discovery target and drive ...
... , Inc ... called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as Chief Business ... in September 2009, Zyngenia has made tremendous progress in both developing ...
... NEW YORK, Dec. 12, 2011  Fox Insurance Company, a ... NY, announces a judgment in the arbitration between the ... excess of $3.3 million, following a suit against ProCare ... contract.  Nathan M. Barotz, chairman of ...
Cached Biology Technology:Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... -- The International Center for Tropical Agriculture (CIAT) ... a collaborative agreement to sequence 5,000 cassava genotypes, ... wild species of the crop. Cassava is the ... developing countries (after maize, wheat and rice.) Results ...
... exploded in Yambuku, a remote village in Zaire, (now the ... Ebola had emerged, soon earning a grim distinction as one ... up to 90 percent of its victims, and producing a ... Charles Arntzen, a researcher at the Biodesign Institute at Arizona ...
Cached Biology News:Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3BGI and CIAT announce collaboration for large-scale genome sequencing of cassava 2BGI and CIAT announce collaboration for large-scale genome sequencing of cassava 3Defensive measures: Toward a vaccine for Ebola 2Defensive measures: Toward a vaccine for Ebola 3Defensive measures: Toward a vaccine for Ebola 4Defensive measures: Toward a vaccine for Ebola 5
Mol wt: average mol wt16,951.27 Da by calculation...
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... set-up Easy to assemble ... tubes, strips or Nunc 96 Well Amplifications ... tray can be fitted directly into the thermal cycler ... thermal cycler formats of major manufacturers Alphanumerically ...
Biology Products: